283 related articles for article (PubMed ID: 36281789)
1. IGF2BP2 serves as a core m6A regulator in head and neck squamous cell carcinoma.
Hu Y; Chen J; Liu M; Feng Q; Peng H
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281789
[TBL] [Abstract][Full Text] [Related]
2. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
[TBL] [Abstract][Full Text] [Related]
3. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer analysis reveals the pro-oncogenic role of N6-methyladenosine (m6A)-regulated NTMT1 in head and neck squamous cell carcinoma.
Zhao C; Yu M; Li Y
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23603. PubMed ID: 38014887
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of an m6A Reader Gene,
Deng X; Jiang Q; Liu Z; Chen W
Front Mol Biosci; 2020; 7():68. PubMed ID: 32391379
[TBL] [Abstract][Full Text] [Related]
6. Aberrations of m6A regulators are associated with tumorigenesis and metastasis in head and neck squamous cell carcinoma.
Arumugam P; George R; Jayaseelan VP
Arch Oral Biol; 2021 Feb; 122():105030. PubMed ID: 33383437
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Investigation of m6A Regulators for Prognosis in Head and Neck Squamous Cell Carcinoma.
Cheng J; Lyu Y; Cheng Z
J Environ Pathol Toxicol Oncol; 2024; 43(1):45-60. PubMed ID: 37824369
[TBL] [Abstract][Full Text] [Related]
8. The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma.
Li J; Cao J; Liang C; Deng R; Li P; Tian J
Med Oncol; 2022 Jan; 39(4):41. PubMed ID: 35092501
[TBL] [Abstract][Full Text] [Related]
9. Identification of Two m6A Readers
Li S; Wu Q; Liu J; Zhong Y
Front Genet; 2022; 13():903634. PubMed ID: 35646049
[No Abstract] [Full Text] [Related]
10. A Signature of N
Chen J; Lu T; Zhong F; Lv Q; Fang M; Tu Z; Ji Y; Li J; Gong X
Front Immunol; 2022; 13():809872. PubMed ID: 35185897
[TBL] [Abstract][Full Text] [Related]
11. IGF2BP2 promotes pancreatic carcinoma progression by enhancing the stability of B3GNT6 mRNA via m6A methylation.
Cao P; Wu Y; Sun D; Zhang W; Qiu J; Tang Z; Xue X; Qin L
Cancer Med; 2023 Feb; 12(4):4405-4420. PubMed ID: 35908253
[TBL] [Abstract][Full Text] [Related]
12. Prognostic biomarker GSTK1 in head and neck squamous cell carcinoma and its correlation with immune infiltration and DNA methylation.
Feng Y; Zhou YH; Zhao J; Su XL; Chen NX; Zhao YQ; Ye Q; Hu J; Ou-Yang ZY; Zhong MM; Yang YF; Han PJ; Guo Y; Feng YZ
Front Genet; 2023; 14():1041042. PubMed ID: 36936420
[No Abstract] [Full Text] [Related]
13. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
Hu R; Lu M; She L
Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
[TBL] [Abstract][Full Text] [Related]
15. Identification of the MMP family as therapeutic targets and prognostic biomarkers in the microenvironment of head and neck squamous cell carcinoma.
Liu M; Huang L; Liu Y; Yang S; Rao Y; Chen X; Nie M; Liu X
J Transl Med; 2023 Mar; 21(1):208. PubMed ID: 36941602
[TBL] [Abstract][Full Text] [Related]
16. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
Huang J; Liang B; Wang T
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
[TBL] [Abstract][Full Text] [Related]
17. TMED2/9/10 Serve as Biomarkers for Poor Prognosis in Head and Neck Squamous Carcinoma.
Gao W; Zhang ZW; Wang HY; Li XD; Peng WT; Guan HY; Liao YX; Liu A
Front Genet; 2022; 13():895281. PubMed ID: 35754792
[No Abstract] [Full Text] [Related]
18. METTL14 inhibits malignant progression of oral squamous cell carcinoma by targeting the autophagy-related gene RB1CC1 in an m6A-IGF2BP2-dependent manner.
Liang J; Cai H; Hou C; Song F; Jiang Y; Wang Z; Qiu D; Zhu Y; Wang F; Yu D; Hou J
Clin Sci (Lond); 2023 Sep; 137(17):1373-1389. PubMed ID: 37615536
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatics analyses proposed xenotropic and polytropic retrovirus receptor 1 as a potential diagnostic and prognostic biomarker and immunotherapeutic target in head and neck squamous cell carcinoma.
Wang L
Auris Nasus Larynx; 2023 Feb; 50(1):134-150. PubMed ID: 35690506
[TBL] [Abstract][Full Text] [Related]
20. Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma.
Zhang Y; Li L; Ye Z; Zhang L; Yao N; Gai L
Ann Transl Med; 2021 Oct; 9(20):1554. PubMed ID: 34790760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
